HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
HRMYHarmony Biosciences(HRMY) Prnewswire·2024-04-11 20:05

Harmony Biosciences与Bioprojet签署独家许可协议 - TPM-1116代表了一种新的化学系列的OX2R激动剂，具有潜力成为最佳临床配置文件[1] - Harmony Biosciences将向Bioprojet支付2505万美元的前期许可费，以获得在美国和拉丁美洲领土独家开发、生产和商业化TPM-1116的权利[1] 开发、生产和商业化TPM-1116 - Harmony将根据开发和监管里程碑的实现支付高达1.275亿美元的费用，并根据销售里程碑的实现支付高达2.4亿美元的费用[1] - Harmony将在授权领土的产品销售中支付中等百分比的版税率[1]